Key result
Circulating CTRP9 levels are significantly lower in patients with CAD versus those without.
Why the study?
Studies have reported conflicting results regarding circulating CTRP9 levels in patients with and without coronary artery disease.
Are circulating CTRP9 levels associated with coronary artery disease?
Meta-Analysis
Are circulating CTRP9 levels associated with coronary artery disease?
Circulating CTRP9 levels are significantly lower in patients with coronary artery disease compared to those without, suggesting a potential role as a biomarker.
Answers are grounded in this paper and cite their sources.
May support CTRP9 as CAD biomarker; hypothesis-generating and needs prospective validation before clinical adoption.
Background: C1q tumor necrosis factor (TNF) related proteins 9 (CTRP9) is a novel adipocytokine that has been shown to have a cardioprotective effect in coronary artery disease (CAD). However, there are conflicting results on circulating levels of CTRP9 in patients with and without CAD. This meta-analysis was conducted to investigate the association between circulating CTRP9 levels and CAD. Objective: The aim of this meta-analysis was to re-examine the relationship between circulating CTRP9 levels and CAD. Methods: We searched PubMed, Web of Science, Embase, Cochrane Library, CNKI, VIP, Wanfang Data, and CBM for relevant studies up to October 2023, and 193 articles were identified. After reading the title, abstract and full text, a total of 25 articles were included in this meta-analysis. A prespecified protocol registered at INPLASY was followed (INPLASY202450066). Due to the high heterogeneity, we performed subgroup analyses and meta-regression based on patient characteristics, complications, clinical biochemical indicators, coronary artery lesion, and CAD classification. Publication bias was assessed using Egger's linear regression tests, Begg's rank correlation tests, and funnel plots. Subgroup analysis and meta-regression findings demonstrated that observed heterogeneity could be attributed to population distribution. Patient characteristics (year of publication, patients' age, and BMI), complications (diabetes and type 2 diabetes mellitus (T2DM)), clinical biochemical indicators, coronary artery lesion (stability of coronary atherosclerotic plaque, and the number of diseased coronary vessels), and classification of CAD were not identified as source of heterogeneity. Conclusions: The meta-analysis confirmed that circulating CTRP9 levels in CAD patients are significantly lower than those in patients without CAD. The association may be modified by the population distribution.
No takes yet. Share an insight, caveat, or question.
Zhu et al. (2024) conducted a meta-analysis in Coronary artery disease. Circulating CTRP9 levels vs. Patients without CAD was evaluated on Circulating CTRP9 levels (p== 0.001). Circulating CTRP9 levels in patients with coronary artery disease were lower than those in patients without CAD.
Synapse has enriched 10 related papers. Consider them for comparative context: